Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Fennec Pharmaceuticals Announces NICE Positive Recommendation for Pedmarqsi®
Details : Pedmarqsi (anhydrous sodium thiosulfate) is the first and only intracellular oxidative stress inhibitor, treatment available in England for cisplatin-induced ototoxicity in 1 month-17 years of age.
Product Name : Pedmarqsi
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
December 20, 2024
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Approved FDF
Sponsor : Norgine
Deal Size : $271.6 million
Deal Type : Licensing Agreement
Fennec and Norgine License PEDMARQSI for Europe, Australia, New Zealand
Details : Norgine will commercialize Pedmarqsi (sodium thiosulfate) in Europe, Australia, and New Zealand, the first approved therapy in the EU and UK to prevent cisplatin-induced ototoxicity.
Product Name : Pedmarqsi
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : $43.4 million
March 18, 2024
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Approved FDF
Sponsor : Norgine
Deal Size : $271.6 million
Deal Type : Licensing Agreement
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Approved FDF
Sponsor : Petrichor Healthcare
Deal Size : $20.0 million
Deal Type : Financing
Fennec Announces Incremental $5 Million Investment from Petrichor
Details : The net proceeds will be used by the company for the commercialization of Pedmark (sodium thiosulfate), the only approved therapy for reducing the risk of hearing loss in pediatric cancer patients who receive treatment with platinum-based chemotherapy.
Product Name : Pedmark
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Undisclosed
May 12, 2023
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Approved FDF
Sponsor : Petrichor Healthcare
Deal Size : $20.0 million
Deal Type : Financing
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pedmarqsi™ (sodium thiosulfate) is the only FDA approved intravenous therapy, to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors.
Product Name : Pedmarqsi
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
March 31, 2023
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pedmark® (sodium thiosulfate) is the only FDA approved intravenous therapy, to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors.
Product Name : Pedmark
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
January 31, 2023
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pedmark® (sodium thiosulfate) is the only FDA approved intravenous therapy, to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors.
Product Name : Pedmark
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
January 25, 2023
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase III
Sponsor : Petrichor Healthcare
Deal Size : $25.0 million
Deal Type : Financing
Fennec Pharmaceuticals Closes First $5 Million Investment From Petrichor
Details : Under the terms of the agreement, an additional is to be funded upon the potential U.S. Food and Drug Administration approval of PEDMARK (sodium thiosulfate) by September 30, 2022 and satisfaction of other closing conditions.
Product Name : Pedmark
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Undisclosed
August 22, 2022
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase III
Sponsor : Petrichor Healthcare
Deal Size : $25.0 million
Deal Type : Financing
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PEDMARK is a small molecule, unique formulation of STS, is administered 6 hours post completion of cisplatin infusion in an intravenous bolus dose over 15 minutes, has potential to reduce the incidence of chemotherapy-induced hearing loss.
Product Name : Pedmark
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
April 27, 2022
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PEDMARK™ (a unique formulation of sodium thiosulfate), is currently under evaluation by EMA, as an essential chemotherapeutic agent for many pediatric malignancies also has received breakthrough therapy and fast track designation.
Product Name : Pedmark
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
March 24, 2022
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase III
Sponsor : Petrichor Healthcare Capital Management
Deal Size : $45.0 million
Deal Type : Financing
Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor
Details : PEDMARK (sodium thiosulfate), has been studied by cooperative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity, the clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. Both studies have been completed.
Product Name : Pedmark
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Undisclosed
January 08, 2022
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase III
Sponsor : Petrichor Healthcare Capital Management
Deal Size : $45.0 million
Deal Type : Financing